Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN: Rocuronium in Paediatric ARDS
NCT02902055Phase 4Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Rocuronium with Placebo (2 arms). Primary endpoint: Cumulative respiratory morbidity at 12 months. Started Dec 2019; status: terminated.
02
Drugs
rocuronium
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02902055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902055.